450 related articles for article (PubMed ID: 17443154)
1. Moment of reckoning.
Wadman M
Nature; 2007 Apr; 446(7138):844-5. PubMed ID: 17443154
[No Abstract] [Full Text] [Related]
2. The problem of new uses.
Eisenberg RS
Yale J Health Policy Law Ethics; 2005; 5(2):717-39. PubMed ID: 16052897
[No Abstract] [Full Text] [Related]
3. Evaluating drug effects in the post-Vioxx world: there must be a better way.
Avorn J
Circulation; 2006 May; 113(18):2173-6. PubMed ID: 16684873
[No Abstract] [Full Text] [Related]
4. They are from the government and they really are here to help you.
Woosley RL
J Clin Pharmacol; 2008 Feb; 48(2):142-3. PubMed ID: 18199889
[No Abstract] [Full Text] [Related]
5. Drug safety on trial.
Nature; 2005 Mar; 434(7033):545. PubMed ID: 15800579
[No Abstract] [Full Text] [Related]
6. Clinical trials in the wake of Vioxx: requiring statistically extreme evidence of benefit to ensure the safety of new drugs.
Roth-Cline MD
Circulation; 2006 May; 113(18):2253-9. PubMed ID: 16684875
[No Abstract] [Full Text] [Related]
7. Communicating with the FDA: the "third rail" of a new model for drug development.
Stanski DR; Orloff JJ
J Clin Pharmacol; 2008 Feb; 48(2):144-5. PubMed ID: 18199890
[No Abstract] [Full Text] [Related]
8. Drug safety special: the safety catch.
Wadman M
Nature; 2005 Mar; 434(7033):554-6. PubMed ID: 15800591
[No Abstract] [Full Text] [Related]
9. What ails the FDA?
Okie S
N Engl J Med; 2005 Mar; 352(11):1063-6. PubMed ID: 15784660
[No Abstract] [Full Text] [Related]
10. Progress and deficiencies in the registration of clinical trials.
Wood AJ
N Engl J Med; 2009 Feb; 360(8):824-30. PubMed ID: 19228628
[No Abstract] [Full Text] [Related]
11. Withdrawal syndrome.
Nat Med; 2004 Nov; 10(11):1143. PubMed ID: 15516887
[No Abstract] [Full Text] [Related]
12. Trouble at the office.
Allison M
Nat Biotechnol; 2008 Sep; 26(9):967-9. PubMed ID: 18779797
[No Abstract] [Full Text] [Related]
13. Drug review "behind the curtain": a response to Professor Struve.
O'Reilly JT
Cornell Law Rev; 2008 Jul; 93(5):1075-90. PubMed ID: 18618971
[No Abstract] [Full Text] [Related]
14. What ails the FDA?
Cohen FJ
N Engl J Med; 2005 Jun; 352(24):2554. PubMed ID: 15962406
[No Abstract] [Full Text] [Related]
15. Suppressed study raises spectre of flawed drug regulation in US.
Marris E
Nature; 2004 Dec; 432(7017):537. PubMed ID: 15577867
[No Abstract] [Full Text] [Related]
16. Clinical trials performed for the new drug approval process in the United States: standard methods and alternative methods.
Browne TR
Epilepsy Res Suppl; 1993; 10():31-44. PubMed ID: 8251105
[No Abstract] [Full Text] [Related]
17. Drive for drugs leads to baby clinical trials.
Nature; 2006 Mar; 440(7083):406-7. PubMed ID: 16554774
[No Abstract] [Full Text] [Related]
18. New clinical trials policy at FDA.
Vastag B
Nat Biotechnol; 2006 Sep; 24(9):1043. PubMed ID: 16964196
[No Abstract] [Full Text] [Related]
19. Don't blame it all on the bogey.
Day M
BMJ; 2007 Jun; 334(7606):1250-1. PubMed ID: 17569929
[TBL] [Abstract][Full Text] [Related]
20. Epo, by any other name.
Nature; 2007 Sep; 449(7160):259. PubMed ID: 17882170
[No Abstract] [Full Text] [Related]
[Next] [New Search]
